ABVC BioPharma prices $1.75M registered direct offering of 500,000 shares/pre-funded warrants at $3.50/share

ABVC BIOPHARMA, INC.

Gross proceeds of $1.75M from sale of 300,000 shares and 200,000 pre-funded warrants at $3.50/share.
Single institutional investor; closing expected July 31, 2023.
Net proceeds for R&D, working capital, and possible debt repayment.
Wilmington Capital Securities acting as exclusive placement agent.
Offering made under effective shelf registration statement (File No. 333-260588).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at gross proceeds of $1,750,000 (effective 2023-07-27).

Action: entry
Agreement: equity purchase
Counterparty: certain investors (the "Purchasers")
Value: gross proceeds of $1,750,000
Effective: 2023-07-27

Exact text from the filing

ABVC BioPharma, Inc. (the “ Company ”) and certain investors (the “ Purchasers ”) entered into that certain securities purchase agreement on July 27, 2023 (the “ Purchase Agreement ”) relating to the offer and sale of 300,000 shares of common stock (the “ Shares ”), par value $0.001 per share (the “ Common Stock ”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share (the “ Pre-funded Warrants ”), in a registered direct offering (the “ Offering ”).

View on SEC.gov

Browse all material agreements →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-060140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.